拉曼光谱（RS）是一种很有前景的脑肿瘤检测方法。 RS 过程中获得的近红外自发荧光 (AF) 为肿瘤识别提供了额外的有用信息，并与 RS 进行比较研究，以原位描绘脑肿瘤。拉曼光谱与 AF 一起在实体瘤内和肿瘤边界原位采集常规脑肿瘤手术（218 个谱；神经胶质瘤 WHO II-III，n = 6；GBM，n = 10；转移瘤，n = 10；脑膜瘤，n = 3）。用于肿瘤原位识别的组织分类根据离体数据进行训练（375 个光谱；神经胶质瘤/GBM 患者，n = 20；转移瘤，n = 11；脑膜瘤，n = 13；癫痫海马，n = 4）。均为原位离体数据显示，脑肿瘤中的AF强度低于边缘区域和正常脑组织。此外，AF 强度与 1437 cm- 1 处脂质对应的拉曼带强度呈正相关，而与 1260 cm- 1 处蛋白质带的强度呈负相关。原位 AF 和 RS 数据集与外科医生对组织类型的评估相匹配，正确率分别为 0.83 和 0.84。与在选定测量位置切除的组织活检的组织病理学相比，获得了类似的正确率（AF：0.80，RS：0.83）。光谱学已成功集成到现有的神经外科工作流程中，并且可以根据离体数据对原位光谱数据进行分类。 RS 证实了其检测脑肿瘤的能力，而 AF 则成为术中肿瘤描绘的竞争方法。© 2024。作者。

Raman spectroscopy (RS) is a promising method for brain tumor detection. Near-infrared autofluorescence (AF) acquired during RS provides additional useful information for tumor identification and was investigated in comparison with RS for delineating brain tumors in situ.Raman spectra were acquired together with AF in situ within the solid tumor and at the tumor border during routine brain tumor surgeries (218 spectra; glioma WHO II-III, n = 6; GBM, n = 10; metastases, n = 10; meningioma, n = 3). Tissue classification for tumor identification in situ was trained on ex vivo data (375 spectra; glioma/GBM patients, n = 20; metastases, n = 11; meningioma, n = 13; and epileptic hippocampi, n = 4).Both in situ and ex vivo data showed that AF intensity in brain tumors was lower than that in border regions and normal brain tissue. Moreover, a positive correlation was observed between the AF intensity and the intensity of the Raman band corresponding to lipids at 1437 cm- 1, while a negative correlation was found with the intensity of the protein band at 1260 cm- 1. The classification of in situ AF and RS datasets matched the surgeon's evaluation of tissue type, with correct rates of 0.83 and 0.84, respectively. Similar correct rates were achieved in comparison to histopathology of tissue biopsies resected in selected measurement positions (AF: 0.80, RS: 0.83).Spectroscopy was successfully integrated into existing neurosurgical workflows, and in situ spectroscopic data could be classified based on ex vivo data. RS confirmed its ability to detect brain tumors, while AF emerged as a competitive method for intraoperative tumor delineation.© 2024. The Author(s).